{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-129378","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2024-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.260297+00:00","generated_at":"2026-05-29T02:35:53.714041+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Structure Therapeutics selects lead oral amylin agonist ACCG-2671 for obesity; Phase 1 start by end-2025","bullets":["ACCG-2671 is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) designed for once-daily oral dosing.","Preclinical data show cagrilintide-like efficacy with potent target engagement and favorable safety profile.","Phase 1 clinical development expected to begin by year end 2025.","Company believes ACCG-2671 could serve as backbone therapy for fixed-dose oral combinations with GLP-1 candidate GSBR-1290.","Structure is developing a series of amylin-based candidates using its GPCR structure-based drug discovery platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-129378","json":"https://secwatch.observer/filing/0001104659-24-129378.json","markdown":"https://secwatch.observer/filing/0001104659-24-129378.md","text":"https://secwatch.observer/filing/0001104659-24-129378.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924129378/0001104659-24-129378-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924129378/tm2431274d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:35:53.714041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}